HC Wainwright Predicts NextCure’s Q2 Earnings (NASDAQ:NXTC)

NextCure, Inc. (NASDAQ:NXTC) – Equities researchers at HC Wainwright lifted their Q2 2026 earnings estimates for NextCure in a research note issued to investors on Wednesday, July 15th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($1.93) per share for the quarter, up from their previous forecast of ($2.09). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for NextCure’s current full-year earnings is ($7.90) per share. HC Wainwright also issued estimates for NextCure’s Q3 2026 earnings at ($2.00) EPS, Q4 2026 earnings at ($2.07) EPS, FY2026 earnings at ($7.88) EPS, FY2027 earnings at ($3.33) EPS, FY2028 earnings at ($3.18) EPS and FY2029 earnings at ($2.17) EPS.

NextCure (NASDAQ:NXTC) last released its earnings results on Thursday, May 7th. The company reported ($1.87) EPS for the quarter, topping analysts’ consensus estimates of ($2.10) by $0.23.

Other research analysts also recently issued reports about the company. Weiss Ratings downgraded NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. Zacks Research upgraded NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $19.00.

NextCure Price Performance

NASDAQ NXTC opened at $6.17 on Friday. NextCure has a one year low of $1.55 and a one year high of $15.74. The firm has a market cap of $22.27 million, a P/E ratio of -0.36 and a beta of 1.42. The stock’s 50-day moving average is $4.51 and its 200-day moving average is $9.32.

Institutional Trading of NextCure

Hedge funds and other institutional investors have recently modified their holdings of the stock. Marshall Wace LLP acquired a new position in shares of NextCure in the fourth quarter valued at about $160,000. Millennium Management LLC acquired a new position in shares of NextCure during the 4th quarter worth approximately $185,000. Geode Capital Management LLC increased its holdings in shares of NextCure by 18.6% during the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock worth $329,000 after purchasing an additional 3,636 shares during the period. Renaissance Technologies LLC raised its position in shares of NextCure by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after buying an additional 5,300 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new stake in shares of NextCure in the fourth quarter valued at approximately $988,000. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.